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OBJECTIVES The objective of this study was to evaluate the addition of intravenous (IV) tezosentan to
standard therapy for patients with pulmonary edema.
BACKGROUND Tezosentan is an IV nonselective endothelin (ET)-1 antagonist that yields favorable
hemodynamic effects in patients with acute congestive heart failure (CHF).
METHODS Pulmonary edema was defined as acute CHF leading to respiratory failure, as evidenced by an
oxygen saturation (SO2) 90% by pulse oxymeter despite oxygen treatment. All patients
received oxygen 8 l/min through a face mask, 3 mg of IV morphine, 80 mg of furosemide, and
1 to 3 mg/h continuous drip isosorbide-dinitrate according to their blood pressure level and
were randomized to receive a placebo or tezosentan (50 or 100 mg/h) for up to 24 h.
RESULTS Eighty-four patients were randomized. The primary end point, the change in SO2 from
baseline to 1 h, was 9.1  6.3% in the placebo arm versus 7.6  10% in the tezosentan group
(p  NS). The incidence of death, recurrent pulmonary edema, mechanical ventilation, and
myocardial infarction during the first 24 h of treatment was 19% in both groups. Reduced
baseline SO2, lower echocardiographic ejection fraction, high baseline mean arterial blood
pressure (MAP), and inappropriate vasodilation (MAP reduction at 30 min of 5% or
30%) correlated with worse outcomes. A post-hoc analysis revealed that the outcome of
patients who received only 50 mg/h tezosentan was better than patients in the placebo group
whereas patients receiving 100 mg/h had the worst outcomes.
CONCLUSIONS In the present study, tezosentan (an ET-1 antagonist) did not affect the outcome of
pulmonary edema, possibly because of the high dose used. (J Am Coll Cardiol 2003;41:
204–10) © 2003 by the American College of Cardiology Foundation
In previous studies (1–4) it was demonstrated that acute
cardiogenic pulmonary edema results from a rapidly deteri-
orating cycle of events in which patients with reduced
baseline systolic and diastolic reserve are faced with an acute
increase in systemic vascular resistance and, hence, after-
load. This causes an acute decompensated state, leading to
decreased peripheral perfusion, neurohormonal activation,
decreasing left ventricular function, and increasing vascular
resistance. The result of this vicious cycle is an increase in
left ventricular end-diastolic pressure that is transmitted
backwards to the pulmonary vasculature, causing an acute
increase in pulmonary capillary pressure and the transuda-
tion of fluid from the intravascular compartment to the lung
interstitium and alveoli, leading in turn to the full-blown
syndrome of acute cardiogenic pulmonary edema.
Endothelin (ET)-1 is one of the most potent and
long-lasting endogenous vasoconstrictors isolated to date
(5). It is elevated in certain clinical situations, including
congestive heart failure (CHF) (6). Endothelin-1 (7) and
big ET (8) are markedly elevated in chronic CHF (9), and
serum levels correlate with prognosis. Tezosentan is an
intravenous (IV) nonselective ET-1 blocker. In two separate
phase II studies in patients with severe chronic CHF
(10,11) and in one phase III study in patients with acute
CHF (G. Torre-Amione et al., unpublished data, 2002), it
was demonstrated that maximal hemodynamic effects of
tezosentan in patients with chronic heart failure can be
accomplished with doses of 25 to 50 mg/h. These beneficial
effects yielded improved cardiac index and reduced systemic
and pulmonary vascular resistance, as well as pulmonary
capillary wedge pressure.
Therefore, the main assumption of the Randomized
Intravenous TeZosentan (RITZ)-5 study was that because
ET-1 is a potent vasoconstrictor occurring in high levels in
patients with CHF, by rapidly blocking its action with the
receptor antagonist tezosentan, significant vasodilation will
occur, which then will improve the condition of patients
more rapidly (that is, a faster improvement in oxygen
saturation [SO2]) and decrease the rate of refractory pul-
monary edema.
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PATIENTS AND METHODS
Study design. A prospective, double-blind, placebo-
controlled, multicenter, parallel (1:1), phase III study to
assess the efficacy and safety of IV tezosentan in addition to
standard therapy in patients with acute pulmonary edema
was conducted.
Inclusion criteria. Men or nonpregnant women (age 18
years) with severe acute pulmonary edema defined as acute
CHF exacerbation accompanied by an SO2 90% while
receiving oxygen 8 l/min who were able and willing to sign
an informed consent were included in the study. A chest
X-ray was not used for inclusion because it is not available
on mobile intensive care units, which is where most patients
were recruited.
Exclusion criteria. Exclusion criteria for patients were as
follows: systolic blood pressure 110 mm Hg; hemody-
namically significant arrhythmias; acute coronary syndrome
with ST-segment elevation; active myocarditis; hypertro-
phic obstructive cardiomyopathy; stenotic valvular disease;
restrictive or constrictive pathology; congenital heart dis-
ease; or pericarditis. Also excluded were patients with:
noncardiac pulmonary edema; clinical evidence of digoxin
toxicity; hemodynamic supporting devices; acute or chronic
dialysis; systemic illnesses; sepsis; terminal illness; or previ-
ous exposure to tezosentan.
Study medication. Intravenous tezosentan (Actelion Ltd.,
Allschwil, Switzerland) 50 mg/h for 15 to 30 min followed
by a maintenance drip of 50 to 100 mg/h for up to 24 h.
Protocol. Patients admitted with acute pulmonary edema
received conventional therapy defined as oxygen (8 l/min via
100% nonrebreather mask), IV furosemide (80 mg bolus),
IV isosorbide dinitrate drip (1 to 3 mg/h), and IV morphine
sulfate (3 mg bolus). Randomized patients received either
IV tezosentan or placebo. Patients were followed up for 30
days after enrollment.
Concomitant medications. Parenteral inotropes, sympa-
thomimetics, or vasodilators initiated at least 2 h before
randomization could continue to be used during the study.
However, the dose had to be kept constant for at least 6 h
after the initiation of the study medication. Increasing the
doses of these medications was reserved for those with
worsening CHF or an inadequate response to the protocol.
Primary end point. The primary end point was defined as
the change from baseline to 60 min in arterial SO2 as
measured by pulse oxymetry.
Secondary end points. The secondary end points were as
follows:
1. death, mechanical ventilation, recurrent pulmonary
edema, or new myocardial infarction (MI) during first
24 h of treatment;
2. a change in SO2 from baseline to 15, 30, 45, 60, 75, 90,
120, 240, or 360 min;
3. all cause mortality and rehospitalizations within 30 days
of treatment initiation;
4. evidence of acute MI in the first 24 h of treatment, and
5. initiation or increase in treatment of IV inotropic,
sympathomimetic, or vasodilator therapy for heart failure
during the first 24 h.
Predictors of outcome. Although measures of treatment
success in pulmonary edema are not generally available, we
have suggested, based on previous studies (1–4), some
criteria for treatment success—an increase in SO2, specifi-
cally to above 95%—and treatment failure —the occurrence
of refractory pulmonary edema, that is, pulmonary edema
not improving despite the abovementioned treatment, in-
stead requiring further aggressive vasodilator treatment or
mechanical ventilation and acute MI during the first 24 h of
treatment. Based on those studies, important predictors of
treatment success or failure included: baseline SO2 (as a
measure of disease severity); echocardiographic resting ejec-
tion fraction (EF) as a measure of lower left ventricular
contractility reserve; and higher baseline mean arterial blood
pressure (MAP) as a measure of higher baseline systemic
vascular resistance. We also analyzed whether appropriate
vasodilation (defined as a decrease of 5% to 30% in MAP at
30 min since treatment initiation [12]) as a measure of
appropriate therapeutic response to vasodilators was a pre-
dictor of treatment success or failure.
Statistical analysis. The planned sample size of 50 patients
randomized equally to tezosentan or placebo was calculated
to detect with 90% power a difference between treatments of
6% (standard deviation  6%) on the mean change from
baseline to 1 h in SO2 at a two-sided alpha level of 0.05
using the Student t test. The sample size estimation in this
situation depends exclusively on the effect size, which is 1.0.
Subsequently, a new requirement was determined to have
sufficient power to detect a difference in an exploratory
analysis of the incidence of the combined end point of
death, mechanical ventilation, recurrent pulmonary edema,
or new MI during the first 24 h of randomized therapy. To
detect a clinically relevant reduction in event rates from 50%
in the placebo arm to 15% in the tezosentan arm by means
of the Fisher exact test, the sample size was increased to 84
patients (42 patients per treatment arm). As a result of this
increase in sample size, the power of the hypothesized test
on the primary end point increased from 90% to 99%.
Alternatively, with a sample size of 42 patients per group, a
two-sided alpha level of 0.05, and the common standard
deviation of 6%, the study has 90% power to detect a
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difference of 4.3% in the primary end point as statistically
significant.
Location and scale statistics were calculated and displayed
for the numeric parameters (mean, standard deviation,
standard error of the mean, 95% confidence interval of the
mean, median, first, and third quartiles, minimum and
maximum). Exploratory p values for comparisons were from
the Student t test.
Proportions and 95% confidence intervals were computed
for the incidences. Exploratory p values for comparisons
were from the Fisher exact test.
Kaplan-Meier estimates were computed for the propor-
tions of event-free patients for the different events defined
in the protocol. Exploratory p values for comparisons were
from the log-rank test.
Statistical analyses were based on the intention-to-treat
population. All p values were two-sided, with a value of p
0.05 considered significant.
RESULTS
Baseline characteristics. As seen in Table 1, the two study
arms were similar and well balanced.
Study end points. At 60 min, the improvement in arterial
SO2 was similar in the tezosentan and placebo arms (7.6 
10.0 vs. 9.1  6.3, p  0.29). The rest of the end points
assessed were not different between the two arms. In the
30-day analysis, there were also no significant differences
between the tezosentan and placebo arms. Regarding safety,
hypotension was more common in the tezosentan arm (19%
vs. 38%, p  0.05), although this did not occur during the
first hour of treatment, when the patients were in the acute
phase of pulmonary edema, but rather during the mainte-
nance phase. Also, although no statistically significant
difference in the rate of renal failure was observed when
comparing the two treatment arms, there was a statistically
significant larger mean rise in serum creatinine in the
tezosentan arm (3  17 mol/l vs. 19  29 mol/l, p 
0.024) (Table 2). Concomitant medications administered
during the study period are presented in Table 3.
Predictors of outcome in patients with acute pulmonary
edema. In analyzing the results of our study we found that
lower baseline SO2, higher baseline MAP, and lower
baseline echocardiographic EF were predictors of limited
treatment success as measured by lower 1-h SO2 and
increased rate of refractory pulmonary edema or MI at 24 h
follow-up whereas appropriate vasodilation was a predictor
of improved treatment success (Tables 4 to 6). We have also
performed an analysis of these predictors in patients in the
placebo group only, and the effect of these predictors was
virtually identical. Hence, the results of the whole group are
presented.
Post-hoc analysis of the effect of tezosentan. Because we
did not observe any significant effect of tezosentan after the
planned analysis of the study, we performed two post-hoc
analyses of the data.
First, we compared the time-course of blood pressure
decrease in the tezosentan and placebo arms both during the
first hour as well as during 24 h of treatment (Figs. 1A and
1B). This analysis showed that adding tezosentan to stan-
dard treatment for acute cardiogenic pulmonary edema did
not lead to further decrease in blood pressure during the first
hour of treatment (Fig. 1A). However, thereafter, tezosen-
tan induced a significant decrease in blood pressure lasting
up to 6 h (Fig. 1B), necessitating down-titration of the
tezosentan dose in many patients.
Second, we analyzed separately the time-to-death or
recurrent pulmonary edema in patients who received pla-
cebo versus those receiving tezosentan. Furthermore, the
time-course in patients who received tezosentan 50 mg/h
versus those receiving 100 mg/h was analyzed separately
(Fig. 2), although this was not a prespecified analysis and
patients had not been randomized to one of the two doses.
These two doses had at that time been studied in the
randomized, parallel-group, placebo-controlled RITZ-2
Table 1. Baseline Patient Characteristics
Baseline Characteristics
Placebo
(n  42)
Tezosentan
(n  42) p Value
Females (%) 42.9 52.4 0.51
Age (yrs) [mean  SD] 73.2  8.4 74.2  11.7 0.64
Left ventricle EF (%) 40.6  11.6 42.2  11.9 0.47
Patients with normal EF (%) 12 14 0.85
Baseline SO2 (%) 86.7  3.8 85.7  7.7 0.46
Baseline heart rate (beats/min) 95.4  23.3 97.4  25.4 0.63
Baseline respiratory rate (respirations/min) 31  7.7 30.3  8.1 0.78
Baseline systolic pressure (mm Hg) 169.6  37 169.3  37.7 0.85
Baseline diastolic pressure (mm Hg) 92.8  21.1 98.2  26.9 0.4
Baseline pulse pressure (mm Hg) 77  29 70  33 0.25
Hypertension (%) 33 (78.6) 35 (83.3) 0.78
Diabetes mellitus (%) 23 (54.8) 24 (57.1) 1.00
Atrial fibrillation (%) 10 (23.8) 8 (19.0) 0.79
Ischemic heart disease (%) 34 (81.0) 33 (78.6) 1.00
Baseline creatinine (mol/l) [mean  SD] 123  42 125  64 0.88
Baseline BUN (mmol/l) [mean  SD] 9.6  4.3 11.1  7.2 0.26
BUN  blood urea nitrogen; EF  ejection fraction; SO2  oxygen saturation.
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study (G. Torre-Amione et al., unpublished data, 2002),
hence, the use of either dose was arbitrarily decided by the
first treating physician. In this analysis we found that the use
of tezosentan 100 mg/h was related to more adverse events
during follow-up as compared with placebo, whereas pa-
tients treated by tezosentan 50 mg/h fared better than
placebo-treated patients.
DISCUSSION
Acute cardiogenic pulmonary edema is a common life-
threatening syndrome. However, its pathogenesis has sel-
dom been explored and no prospective, placebo-controlled
studies have been performed regarding its treatment. We
have recently proposed a novel approach to this syndrome
(3,13). Our main hypothesis was that pulmonary edema is
the end result of a vicious cycle in which decreased cardiac
reserve is met by inappropriate excessive vasoconstriction
induced by inflammatory and neurohormonal activation.
This in turn imposes a severe afterload mismatch on the
already jeopardized left ventricle, causing a further deterio-
ration of its function and leading to an increase in left
ventricular end-diastolic pressure. The increased pressure is
transmitted backwards to the pulmonary veins and capillar-
ies, causing fluid transudation to the lung parenchyma and
alveoli, impairing blood oxygenation and, therefore, reduc-
ing systemic saturation. The end result is a progressive
syndrome of respiratory and circulatory failure that, if
remaining untreated, will cause rapid deterioration and
death.
As previously stated, ET is a strong vasoconstrictor. Its
levels are significantly increased in patients with acute CHF,
and tezosentan is a potent ET antagonist administered
intravenously that was developed specifically for the treat-
ment of acute heart failure. Based on our hypothesis that
pulmonary edema is related to significant peripheral vaso-
constriction (1–4) and our previous experience showing that
vasodilators are effective in the treatment of this syndrome
Table 3. Most Frequent Concomitant Medications
Medication N (%)
Placebo
(n  42)
Tezosentan
(n  42)
Beta-blockers 25 (59.5) 19 (45.2)
Statins 26 (61.9) 18 (42.9)
Antiarrhythmics, class I and III 14 (33.3) 14 (33.3)
Calcium channel blockers 18 (42.9) 12 (28.6)
Digoxin 9 (21.4) 11 (26.2)
Adrenergic and dopaminergic agents 3 (7.1) 10 (23.8)
Spironolactone 12 (28.6) 6 (14.3)
Aspirin 36 (85.7) 35 (83.3)
Table 4. Predictors of Improvement in 60 min SO2 to 95%
Yes No p Value
Refractory pulmonary edema 0 15% 0.016
Acute MI (%) 3 21 0.014
Echocardiographic EF (%) 44  12 35  11 0.05
MAP (mm Hg)
Baseline 125.5  16 115  27 0.09
60 min 100  16 101  19 0.74
MAP decrease at 30 min (%) 12.5  12 5.5  13.5 0.015
Appropriate vasodilatation (%) 62 40 0.05
EF  ejection fraction; MAP  mean arterial blood pressure; MI  myocardial
infarction; SO2  oxygen saturation.
Table 2. End Points at 30, 60 min, 24 h, and 30 days
End Point
Placebo
(n  42)
Tezosentan
(n  42) p Value
By 30 and 60 min
Reduction of mean arterial blood pressure at 30 min
(mean  SD) mm Hg
8  13 11  2 0.4
Arterial oxygen saturation at 60 min (mean  SD) 94.4  3.7 91.6  6.2 0.06
Change of arterial oxygen saturation at 60 min
(Mean%  SD)
9.1  6.3 7.6  10.0 0.29
By 24 h
Mechanical ventilation (%) 1 (2.4) 4 (9.5) 0.36
Hypotension (%) 8 (19) 16 (38.1) 0.05
Acute renal failure (%) 0 (0) 3 (7.1) 0.1
Acute myocardial infarction (%) 4 (9.5) 7 (16.7) 0.34
Cardiogenic shock (%) 1 (2.4) 2 (4.8) 0.32
Recurrent pulmonary edema (%) 4 (9.5) 5 (11.9) 0.73
Refractory pulmonary edema (%) 3 (7.1) 4 (9.5) 0.7
Change in creatinine (mol/l) [mean  SD] 3  17 19  29 0.0024
Total IV furosemide dose (mg/24 h) [mean  SD] 123  75 149  112 0.71
Time to mechanical ventilation (Kaplan-Meier
estimate of event free rate)
Patients with IV inotropes or vasodilator use (%) 7 (16.7) 10 (23.8) 0.58
At 30 days
Mortality (%) 2 (4.8) 5 (11.9) 0.43
Days alive out of hospital (mean  SD) 19.5  7.3 16.5  9.1 0.094
Total hospital days (mean  SD) 10.5  7.3 13.5  9.1 0.094
Readmissions (%) 16 (38.1) 16 (38.1) 1.0
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(1,2), we assumed that tezosentan might be beneficial in the
treatment of acute cardiogenic pulmonary edema.
The present study is the first blinded, placebo-controlled,
prospective, randomized study exploring the role of a novel
treatment modality, that is, tezosentan, an ET-A/B recep-
tor antagonist, in the treatment of acute pulmonary edema.
In the present study, in accordance with our previous
experience, we identified the following four parameters
contributing to treatment success or failure in acute cardio-
genic pulmonary edema:
1. Lower baseline SO2 was related to increased rate of
refractory pulmonary edema. Furthermore, slower im-
provement in SO2 was related to increased incidence of
MI during the first 24 h. This emphasizes the pivotal
role of systemic oxygen desaturation in the final deteri-
oration of patients with pulmonary edema not only in
determining the respiratory failure but also leading to
further circulatory failure caused by myocardial ischemia.
2. Lower baseline echocardiographic EF, which was a
strong predictor of both 1-h SO2 as well as refractory
pulmonary edema.
3. Higher baseline MAP, which was a strong predictor of
both refractory pulmonary edema as well as lower 1-h
SO2.
As previously stated, our hypothesis regarding the patho-
genesis of pulmonary edema involves a critical interaction
between left ventricular contractile reserve and systemic
vascular resistance. The finding that lower echocardio-
graphic EF and higher MAP are both predictors of adverse
outcome in patients with pulmonary edema contributes to
this hypothesis (because high MAP in the presence of low
EF probably indicates high peripheral vascular resistance).
4. Appropriate vasodilation. In accordance with our hy-
pothesis, we found a significant correlation between
appropriate MAP decrease at 30 min (above 5% but
below 30%) and 1-h SO2 and the presence of refractory
pulmonary edema. Because this was not a predefined
study goal, it is difficult to comment on whether this was
related to a better treatment effect or a milder disease
process that was easier to control. However, this finding
is in line with our previous experience regarding the
relationship between appropriate vasodilation and treat-
ment effect (12).
However, the results of this study demonstrate that the
administration of IV tezosentan at the current dose and
dosing schedule did not more effectively treat pulmonary
edema and could lead to side effects, such as hypotension or
renal dysfunction. A few mechanisms, stated in the follow-
ing paragraphs, could explain why an apparently effective
vasodilator did not affect the outcome of these patients.
The role of ET-1 in acute pulmonary edema. Although
there is evidence that ET-1 levels are increased in chronic
heart failure and are associated with worsening symptoms
and adverse prognosis, the role of ET-1 in acute pulmonary
edema has not yet been established. However, because
increased systemic vascular resistance superimposed on re-
duced systolic and diastolic functional reserves is the key
feature of pulmonary edema, ET-1 becomes a possible
suspect. Therefore, it is mandatory in further studies to
document the role of ET-1 in this syndrome.
Specific dose and schedule of administration. Although
similar doses used in previous studies for acute heart failure
resulted in a favorable hemodynamic response, it is possible
that the very same dose may be inappropriate for acute
pulmonary edema. The study medication did decrease MAP
(or systemic vascular resistance) beyond the values obtained
by conventional therapy in the placebo arm. However, as
Figures 1A and 1B clearly demonstrate, these effects were
obtained too late. Because rapid appropriate vasodilation is
essential to treatment success in acute cardiogenic pulmo-
nary edema, this late onset of effect might explain the lack
of early favorable effect of tezosentan in the present study.
However, when the desirable effects were finally obtained
(at 75 to 360 min), they resulted in a more pronounced
decrease in MAP, which can potentially account for the
increased incidence of hypotension and creatinine increase
that was observed in the tezosentan group. Therefore, better
definition of the appropriate (perhaps lower) dose of tezos-
entan is essential for further investigation of this agent in
acute cardiogenic pulmonary edema.
Table 6. Predictors of Acute MI During the First 24 h After
Admission
Yes No p Value
N (%) 11/84 (13) 73/84 (87)
Refractory pulmonary edema
(%)
36 4  0.001
Hypotension (%) 45 26 0.19
SO2 (%)
Baseline 87.5  2 86  6.5 0.45
60 min 89.5  5 93  5 0.035
120 min 89  7 95  5 0.001
360 min 90.5  8 96  5 0.003
SO2 increase at 60 min (%) 2  5.5 7.5  5.5 0.004
MAP at baseline (mm Hg) 133  31 118  26 0.08
MAP  mean arterial blood pressure; MI  myocardial infarction; SO2  oxygen
saturation.
Table 5. Predictors of Refractory Pulmonary Edema
Yes No p Value
N 8/84 (10) 76/84 (90)
Echocardiographic EF (%) 33  6 42  13 0.02
Baseline SO2 (%) 80  14 87  15 0.005
SO2 at 1 h (%) 83  9 94  4  0.001
SO2 increase at 1 h (%) 2.7  10 7  5 0.05
Baseline MAP (mm Hg) 156  27 116  24  0.001
MAP at 1 h (mm Hg) 113  31 99  15 0.04
Baseline pulse 113  23 95  24 0.06
Baseline Respiration rate 35  8 30  8 0.12
EF  ejection fraction, MAP  mean arterial blood pressure; SO2  oxygen
saturation.
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Lack of hemodynamic monitoring. As previously stated,
the therapeutic ratio of most vasodilators is rather narrow.
In recent years two major studies were performed using
vasodilators for the treatment of acute heart failure. These
studies examined the effect of tezosentan (RITZ-1 and -2)
(G. Torre-Amione et al., unpublished data, 2002) (14) and
nitrates versus nesiritide (15). In both studies a beneficial
effect of vasodilator treatment was more pronounced in
patients who were monitored by Swan-Ganz catheters.
Such monitoring was not feasible in the RITZ-5 study. It is
possible that such monitoring or better definition of thera-
peutic goals and exclusion and inclusion criteria would have
enhanced the efficacy of tezosentan and led to a more
pronounced beneficial effect.
Adverse reactions. The safety profile of the dose of tezos-
entan used in the RITZ-5 study is consistent with the
findings of the RITZ-1, -2, and -4 studies that were
performed in patients with acute decompensated heart
failure associated with (RITZ-4) or without (RITZ-1 and
-2) acute coronary syndrome. In particularly, the RITZ-2
study in which two doses (50 and 100 mg/h) of tezosentan
were compared with placebo clearly indicated that the
incidence of hypotension and renal dysfunction were dose
related (G. Torre-Amione et al., unpublished data, 2002).
Figure 1. (A) Mean arterial blood pressure (MAP) decrease during the first 90 min of treatment: tezosentan versus placebo. Filled diamonds  tezosentan
(n  42); filled squares  placebo (n  42). (B) Systolic blood pressure (SBP) decrease during the first 90 min of treatment: tezosentan versus placebo.
BL  baseline.
Figure 2. Time to death, cardiac failure, pulmonary edema, or cardiogenic shock. Patients were treated by placebo or 50 and 100 mg/h of tezosentan.
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The mechanism of renal dysfunction is unknown but could
be related to an excessive vasodilatory effect on the efferent
and/or the afferent arterioles of the renal glomeruli, which is
similar to observations made with angiotensin-converting
enzyme inhibitors (16). Interestingly, in an experimental rat
model of heart failure, the acute administration of tezosen-
tan reduced the associated renal vascular resistance and
increased glomerular filtration, suggesting that if used ap-
propriately, ET blockade might improve renal function in
patients with CHF (17). During the 30-day follow-up, two
and five patients died in the placebo and tezosentan groups,
respectively. Three patients died one (placebo), two, and
three (both on tezosentan) days after stopping treatment
from cardiogenic shock, and the others died more than a week
after stopping treatment from renal failure, septic shock,
pulmonary edema, or sudden death. None of the deaths was
assessed by the investigators as drug related. However, this trial
was too small to assess any effect on mortality.
Excessive vasodilation. Dual ET antagonists, such as
bosentan, were shown to be effective in the treatment of
severe pulmonary arterial hypertension (18). It was specu-
lated that reduction in pulmonary pressures without im-
provement of cardiac function in the presence of left
ventricular failure could be the reason for this observation.
However, this was not seen in patients with CHF treated
chronically with bosentan in the ENdothelin Antagonist
Bosentan for Lowering cardiac Events in heart failure
(ENABLE) study (19). In this trial, increased incidence of
hospitalization for heart failure during the early phase of the
trial was related to fluid retention with no evidence for
increased incidence of pulmonary edema. Also in the
RITZ-2 study (G. Torre-Amione et al., unpublished data,
2002) in which hemodynamic monitoring was performed in
patients with acute CHF receiving the same doses of
tezosentan as in the present study, excessive pulmonary
vasodilation was not observed. Hence, we believe that
excessive pulmonary vasodilation was not the primary rea-
son for the lack of effect of tezosentan in the present study.
Conclusions. The RITZ-5 is the first prospective, ran-
domized, placebo-controlled study exploring a new treat-
ment for acute pulmonary edema. The study failed to show
an improvement of SO2 after 1 h of tezosentan infusion. An
ad-hoc analysis indicated that the outcome of pulmonary
edema is related to baseline SO2, echocardiographic EF and
MAP as well as to the MAP decrease after 30 min of
treatment. Although at the present high doses and treatment
regimen, tezosentan was not found effective in the treatment of
acute pulmonary edema, further studies need to assess the role
of ET-1 in acute pulmonary edema and to re-evaluate carefully
the dose-response curves of tezosentan in this syndrome.
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